Immunosuppression with Cyclosporine A and Mycophenolate Mofetil After Penetrating High-Risk Keratoplasty: A Retrospective Study
Authors:
- Daniel BöhringerDBDaniel Böhringer
- Yevgenia SokolovskaYSYevgenia Sokolovska
- Rainer SundmacherRSRainer Sundmacher
- Thomas ReinhardTRThomas Reinhard
- 1 April 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (8) , 964-968
Abstract
Graft-prognosis after penetrating high-risk keratoplasty has improved considerably with the use of systemic immunosuppressive medications. In this retrospective investigation we analyzed the long-term results of 417 high-risk keratoplasties with systemic immunosuppression (cyclosporine A [CsA] or mycophenolate mofetil [MMF]). A total of 417 high-risk keratoplasties with postoperative systemic immunosuppression were evaluated retrospectively: CsA has been given in 252 keratoplasties since 1987, aiming at blood trough levels of 120 to 150 ng/mL. Systemic MMF at a daily dose of 2 x 1 g was administered in 149 surgical procedures. After 16 high-risk keratoplasties, combined systemic immunosuppression with CsA and MMF was administered. Systemic immunosuppression was scheduled for 6 to 12 months. All patients received fluocortolone 1 mg/kg body weight per day, tapered over 3 weeks, and topical prednisolone acetate 1%, tapered over 5 months. Rejection-free graft survival after 1 year was 75% in the CsA group and 89% in the MMF group; 60% of the grafts in the CsA group and 72% of the grafts in the MMF group were rejection-free 3 years postoperatively (Kaplan-Meier log-rank test P=0.03). Clear graft survival after 1 and 3 years was 92% and 77% (CsA) and 96% and 87% (MMF), respectively. The MMF-treated patients showed fewer side effects than the CsA-treated patients. The side effects attributable to both drugs were reversible. We found a statistically significant, stronger effect of MMF compared with CsA in preventing immune reactions after high-risk keratoplasty, despite a shorter MMF administration compared with CsA. Both systemic immunosuppressants were shown to have comparable potency regarding clear graft survival and were well tolerated.Keywords
This publication has 24 references indexed in Scilit:
- Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trialGraefe's Archive for Clinical and Experimental Ophthalmology, 2001
- Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trialBritish Journal of Ophthalmology, 1999
- MYCOPHENOLATE MOFETIL IN RENAL TRANSPLANTATION: 3-YEAR RESULTS FROM THE PLACEBO-CONTROLLED TRIAL1Transplantation, 1999
- Systemische Cyclosporin-A-Prophylaxe nach Keratoplastiken mit erhöhtem Risiko für Immunreaktionen als einzigem erhöhten RisikofaktorDer Ophthalmologe, 1997
- Akute und chronische Immunreaktionen nach perforierender Keratoplastik mit normalem Immunrisiko*Klinische Monatsblätter für Augenheilkunde, 1997
- MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTSTransplantation, 1997
- ERRATUMTransplantation, 1996
- Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejectionThe Lancet, 1995
- Systemic Cyclosporine in High-risk KeratoplastyOphthalmology, 1994
- Visual, Refractive, and Keratometric Results of Radial KeratotomyArchives of Ophthalmology (1950), 1989